Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity

[1]  G. Petzold,et al.  Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.

[2]  S. Carr,et al.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.

[3]  G. Pinkus,et al.  The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells , 2015, Nature Medicine.

[4]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[5]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[6]  Neeraj Gupta,et al.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. , 2014, The Lancet. Oncology.

[7]  A. Rosenwald,et al.  Disruption of the PRKCD–FBXO25–HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis , 2014, Nature Medicine.

[8]  B. Pégourié,et al.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. Handa,et al.  Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.

[10]  R. Fonseca,et al.  Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. , 2014, Blood.

[11]  Jeremy L. Jenkins,et al.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.

[12]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[13]  S. Carr,et al.  Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.

[14]  H. Handa,et al.  Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.

[15]  R. Chopra,et al.  Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity , 2013, British journal of haematology.

[16]  M. Pagano,et al.  The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer. , 2014, Biochimica et biophysica acta.

[17]  G. Mufti,et al.  Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes , 2013, Annals of Hematology.

[18]  R. Johnstone,et al.  Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy , 2013, Oncogene.

[19]  D. Jelinek,et al.  CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells , 2013, Cell cycle.

[20]  J. Pouysségur,et al.  Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.

[21]  Neil Vargesson,et al.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro , 2013, Proceedings of the National Academy of Sciences.

[22]  K. Taskén,et al.  CD147 in regulatory T cells. , 2013, Cellular immunology.

[23]  E. Kremmer,et al.  Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth , 2013, Proceedings of the National Academy of Sciences.

[24]  D. Sabatini,et al.  MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors , 2012, Nature Genetics.

[25]  Christian Langer,et al.  SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma , 2012, Nature Cell Biology.

[26]  A. Dispenzieri,et al.  Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation , 2012, Leukemia.

[27]  P. L. Bergsagel,et al.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.

[28]  Shao-Chun Wang,et al.  Epidermal Growth Factor Receptor Protects Proliferating Cell Nuclear Antigen from Cullin 4A Protein-mediated Proteolysis* , 2012, The Journal of Biological Chemistry.

[29]  S. Karasawa,et al.  Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.

[30]  P. L. Bergsagel,et al.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.

[31]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[32]  J. Pouysségur,et al.  CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors , 2011, Proceedings of the National Academy of Sciences.

[33]  Chul-Seung Park,et al.  Functional modulation of AMP-activated protein kinase by cereblon. , 2011, Biochimica et biophysica acta.

[34]  D. Esseltine,et al.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. , 2010, Blood.

[35]  Toshihiko Ogura,et al.  Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.

[36]  Y. Li,et al.  Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation , 2010, Journal of cellular and molecular medicine.

[37]  Michele Pagano,et al.  The Cdc14B-Cdh1-Plk1 Axis Controls the G2 DNA-Damage-Response Checkpoint , 2008, Cell.

[38]  H. Dombret,et al.  Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.

[39]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[40]  M. Greene,et al.  CD147 immunoglobulin superfamily receptor function and role in pathology. , 2007, Experimental and molecular pathology.

[41]  R. Roepman,et al.  A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes , 2007, Proteomics.

[42]  Pengbo Zhou,et al.  DCAFs, the missing link of the CUL4-DDB1 ubiquitin ligase. , 2007, Molecular cell.

[43]  M. MacCoss,et al.  Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery , 2006, Nature.

[44]  Chul-Seung Park,et al.  Identification and functional characterization of cereblon as a binding protein for large‐conductance calcium‐activated potassium channel in rat brain , 2005, Journal of Neurochemistry.

[45]  Yi Tang,et al.  Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. , 2005, Cancer research.

[46]  D. Raible,et al.  Zebrafish rx3 and mab21l2 are required during eye morphogenesis. , 2004, Developmental biology.

[47]  Angus G. Dalgleish,et al.  The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.

[48]  G. Schütz,et al.  Selective Inhibition of T Cell Activation Via CD147 Through Novel Modulation of Lipid Rafts1 , 2003, The Journal of Immunology.

[49]  U. Germing,et al.  Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome , 2003, Leukemia.

[50]  B. Zhivotovsky,et al.  Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. , 2003, Blood.

[51]  P. Rameshwar,et al.  Oxygen saturation in the bone marrow of healthy volunteers. , 2002, Blood.

[52]  A. Barclay,et al.  CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression , 2000, The EMBO journal.

[53]  T. Baker,et al.  Lon and Clp family proteases and chaperones share homologous substrate-recognition domains. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  G. Mellin,et al.  The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. , 1962, The New England journal of medicine.